Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krystal BiotechFRA:4KB -0.25%53 EV-to-EBIT is 56.80 as of Jul. 31, 2026, which is 54% above its 10-year median of 36.93. GuruFocus rates FRA:4KB with a GF Score™ of 53/100 and a GF Value™ of €269.95 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 382 Biotechnology companies, Krystal Biotech ranks worse than 85.34% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Krystal Biotech's Enterprise Value for the quarter that ended in Mar. 2026 was €5,630.5 Mil.
Krystal Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €153.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech EV-to-EBIT Related Terms
Krystal Biotech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Krystal Biotech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4KB vs NUVL, HALO, APGE: EV-to-EBIT Comparison
For the Biotechnology subindustry, Krystal Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's EV-to-EBIT falls into.
Krystal Biotech's current Enterprise Value is €8,723.5 Mil.
Krystal Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €153.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech (FRA:4KB) has a EV-to-EBIT of 56.80 as of Jul. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Krystal Biotech and its competitors. This is 54% above median its historical median of 36.93. According to the industry distribution chart, Krystal Biotech ranks #326 out of 382 companies in the Biotechnology industry, placing it in the top 85.3%.
Is Krystal Biotech's EV-to-EBIT too high?
Krystal Biotech's current EV-to-EBIT of 56.80 is 54% above median its 10-year median of 36.93. The Biotechnology industry median EV-to-EBIT is 12.56. Krystal Biotech's value of 56.80 is 352.4% above this industry median. Based on the distribution chart, Krystal Biotech ranks #326 out of 382 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Krystal Biotech has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's EV-to-EBIT compare to NUVL and HALO?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #326 out of 382 companies for EV-to-EBIT. This places Krystal Biotech in the lower half of its industry. The industry median EV-to-EBIT is 12.56. Krystal Biotech's value of 56.80 is 352.4% above this benchmark. While the company's 10-year median is 36.93 vs. the industry median of 12.56, Krystal Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.56, based on 382 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krystal Biotech's current EV-to-EBIT of 56.80 is 352.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Krystal Biotech and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krystal Biotech's current EV-to-EBIT is 56.80, which is 54% above median its own 10-year median of 36.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €269.95, compared to a current price of €313.10 — trading 16% above its estimated fair value. The current EV-to-EBIT is 56.80, which is 54% above median its 10-year median of 36.93 and 352.4% above the Biotechnology industry median of 12.56. Krystal Biotech's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current EV-to-EBIT is 56.80 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued.
The current stock price of €313.10 is trading 16% above its estimated GF Value™ of €269.95.
GuruFocus considers Krystal Biotech to be Modestly Overvalued.
Key valuation signals for FRA:4KB:
EV-to-EBIT: 56.80 (54% above median its 10-year median of 36.93)
GF Value™: €269.95 vs. price of €313.10 (16% above fair value)
Industry Position: 352.4% above the Biotechnology median (#326 of 382)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
53GF Score
Get the complete analysis for FRA:4KB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
